Immunotherapy for the Treatment of Non-Small Cell Lung Cancer
Publication Date: July 17, 2018
Diagnosis for NSCLC
Diagnosis for NSCLC
The analysis of PD-L1 expression by an immunohistochemistry (IHC)-based test to determine PD-L1 expression levels is recommended for all patients with newly diagnosed advanced NSCLC.
- Prior to initiation of immunotherapy, tests recommended by the majority of the Task Force included computerized tomography (CT) of the chest, abdomen, and pelvis and thyroid function tests (in addition to routine lab tests).
PD-L1 testing is recommended in newly diagnosed patients with metastatic disease, including those tested for EGFR/ALK/ROS1 mutations whose results are awaited.
678
Table 1. PD-L1 Assay Characteristics and Performance in NSCLC
Table 1. PD-L1 Assay Characteristics a...
Treatment for NSCLC
...ment for NSCL...
Figure 1. Advanced/Metastatic NSCLC Treatment Algorithm
...Advanced/Metastatic NSCLC Treatment Alg...
...or all newly diagnosed patients is rec...
...rst line pembrolizumab monotherapy sho...
...patients with squamous histology and PD-L1...
...nts with non-squamous, advanced NSCLC and an act...
...umab, nivolumab, or pembrolizumab (TPS...
...ith non-squamous, advanced NSCLC with PD-L1 TPS...
...b is recommended first-line in patients with...
...d be used in stage III patients wh...
Monitoring for NSCLC
...itoring for NSCLC...
...suring and Monitoring Radiographic...
Recognizing, Monitoring and Managing Treatmen...
...e 2. FDA-approved Programmed Cell D...